Population based studies

基于人群的研究

• 批准号: 7966214
• 负责人: Carl Ola Landgren
• 金额: $ 8.1万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7966214
• 关键词: Affect; Biological; Chronic Lymphocytic Leukemia; Development; Disease; Early treatment; Enrollment; Future; Goals; Individual; Intervention; Knowledge; Modeling; Monoclonal gammopathy of uncertain significance; Multiple Myeloma; Patients; Process; Sampling; Science; base; drug development; high risk; improved; mouse model; novel; population based; prospective; treatment trial; tumor; tumor progression

During 2004-2008, I have primarily been using population-based approaches and assessed stored samples in exisiting large biobanks. From the beginning of 2009, I have started to develop novel treatment trials for myeloma patients and also I am in the process of developing new prospective patient studies for individuals affected with high-risk precursor disease. During early 2010, I predict that we will be able to enroll our first precursor patients for early intervention using targeted therapies. These studies will be based on rigorous correlative science aimed to better understand underlying biological mechanisms of tumor development. By taking these approaches, and by constantly developing and improving our concepts, I bevieve that we will be able to delay progression and ultimately cure patients from myeloma in the future. In parallel, we are in the process of developing a myeloma mouse model. The aim of this effort is to develop a model for drug development and better understanding of disease mechanisms.

2004-2008 年间，我主要使用基于人群的方法来评估现有大型生物库中存储的样本。从 2009 年初开始，我开始为骨髓瘤患者开发新的治疗试验，并且正在为患有高危先兆疾病的个体开发新的前瞻性患者研究。 2010 年初，我预测我们将能够招募第一批前期患者，使用靶向疗法进行早期干预。这些研究将基于严格的相关科学，旨在更好地了解肿瘤发展的潜在生物学机制。通过采取这些方法，并不断发展和改进我们的理念，我相信我们将来能够延缓病情进展并最终治愈骨髓瘤患者。与此同时，我们正在开发骨髓瘤小鼠模型。这项工作的目的是开发药物开发模型并更好地了解疾病机制。